- Conditions
- HIV Infection
- Interventions
- Emtricitabine/tenofovir disoproxil
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 15 Years to 22 Years · Male only
- Enrollment
- 167 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Aurora, Colorado • Miami, Florida + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 339
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV/AIDS, Contraception
- Interventions
- tenofovir/emtricitabine, DMPA
- Combination Product · Drug
- Lead sponsor
- Sharon Achilles
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Pre-Exposure Prophylaxis of HIV Infection
- Interventions
- Lenacapavir Tablet, Lenacapavir Injection, Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 253 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • San Diego, California • Washington D.C., District of Columbia + 7 more
- Conditions
- HIV I Infection
- Interventions
- Estradiol
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 14
- States / cities
- San Diego, California • San Francisco, California • Aurora, Colorado + 11 more
- Conditions
- HIV Prevention
- Interventions
- Tenofovir Disoproxil Fumarate/Emtricitabine
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- HIV-1 Infection
- Interventions
- DTG, F/TAF, B/F/TAF, DTG Placebo, F/TAF Placebo, B/F/TAF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 657 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 74
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 53 more
- Conditions
- HIV-1 Infection
- Interventions
- Cenicriviroc 100 mg, Cenicriviroc 200 mg + Truvada, Sustiva + Truvada
- Drug
- Lead sponsor
- Tobira Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 29 more
- Conditions
- HIV Infections
- Interventions
- GSK3640254, ABC/3TC, FTC/TAF, Dolutegravir, Placebo
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Ft. Pierce, Florida • Orlando, Florida + 5 more
- Conditions
- HIV-DDI
- Interventions
- Riociguat (Adempas, BAY 63-2521), ATRIPLA, COMPLERA, STRIBILD, TRIUMEQ, Antiretroviral protease inhibitor
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Boston, Massachusetts
- Conditions
- HIV-1 Infection
- Interventions
- B/F/TAF (Adult Strength), B/F/TAF (Low Dose), B/F/TAF (TOS)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 1 Month to 17 Years
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 10
- States / cities
- Washington D.C., District of Columbia • Ft. Pierce, Florida • Gainesville, Florida + 7 more
- Conditions
- HIV-1 Infection
- Interventions
- DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to DOR/ISL
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 599 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 14 more
- Conditions
- Hiv, Substance Use Disorders
- Interventions
- Descovy 200Mg 25Mg Tablet, PrEP
- Drug · Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Human Immunodeficiency Virus
- Interventions
- Antiretrovirals
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 12 Years to 24 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 3
- States / cities
- Los Angeles, California • New Orleans, Louisiana
- Conditions
- Acquired Immunodeficiency Syndrome, HIV Infections
- Interventions
- PI, RTV, FTC/TDF, Stribild
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 438 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Hayward, California + 28 more
- Conditions
- HIV Infections
- Interventions
- Lenacapavir Injection, Emtricitabine/tenofovir disoproxil fumarate (F/TDF), Emtricitabine/tenofovir alafenamide (F/TAF), Cabotegravir (CAB), Lenacapavir Tablet
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,000 participants
- Timeline
- 2026 – 2029
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 26 more
- Conditions
- HIV Chemoprophylaxis, HIV Preexposure Prophylaxis
- Interventions
- coformulated TDF/FTC
- Drug
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 1,420 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 5
- States / cities
- Washington D.C., District of Columbia • Chicago, Illinois • Jackson, Mississippi + 1 more
- Conditions
- Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
- Interventions
- ATV, DRV, Cobicistat, BR, F/TAF, LPV/r, Third Unboosted Drug, Cobicistat TOS, F/TAF TOS
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 4 Weeks to 17 Years
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 7
- States / cities
- Long Beach, California • Los Angeles, California • Aurora, Colorado + 4 more
- Conditions
- HIV-1-infection
- Interventions
- Lenacapavir, Lenacapavir Tablet, Teropavimab, Zinlirvimab, SBR
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 590 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 2
- States / cities
- Berkeley, Michigan • Annandale, Virginia
- Conditions
- Human Immunodeficiency Virus-1
- Interventions
- maraviroc
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 27
- States / cities
- Los Angeles, California • Norwalk, Connecticut • Washington D.C., District of Columbia + 16 more
- Conditions
- HIV
- Interventions
- Emtricitabine/tenofovir
- Drug
- Lead sponsor
- HIV Prevention Trials Network
- Network
- Eligibility
- 18 Years to 44 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Chapel Hill, North Carolina
- Conditions
- Acquired Immunodeficiency Syndrome, HIV Infections
- Interventions
- NNRTI, FTC/TDF, Stribild
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 439 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Hayward, California + 29 more
- Conditions
- HIV
- Interventions
- Tenofovir (TFV) Alone Vaginal Tablet, Emtricitabine (FTC) Alone Vaginal Tablet, TFV and FTC Combined Vaginal Tablet, Placebo Vaginal Tablet
- Drug
- Lead sponsor
- CONRAD
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 2
- States / cities
- The Bronx, New York • Norfolk, Virginia
- Conditions
- Acquired Immunodeficiency Syndrome, HIV Infections
- Interventions
- Stribild
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 3 more
- Conditions
- HIV-I, Human Immunodeficiency Virus Type 1, Prophylaxis
- Interventions
- Islatravir, Placebo to FTC/TDF, FTC/TDF, Placebo to ISL
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 16 Years to 45 Years · Female only
- Enrollment
- 730 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 10 more